EE200100646A - Melagatraani peaaegu kristalne vorm - Google Patents

Melagatraani peaaegu kristalne vorm

Info

Publication number
EE200100646A
EE200100646A EEP200100646A EEP200100646A EE200100646A EE 200100646 A EE200100646 A EE 200100646A EE P200100646 A EEP200100646 A EE P200100646A EE P200100646 A EEP200100646 A EE P200100646A EE 200100646 A EE200100646 A EE 200100646A
Authority
EE
Estonia
Prior art keywords
melagatran
crystalline form
crystalline
Prior art date
Application number
EEP200100646A
Other languages
English (en)
Estonian (et)
Inventor
Hedstr�m Lena
Lundblad Anita
Ngrd Sofia
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200100646A publication Critical patent/EE200100646A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Liquid Crystal Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EEP200100646A 1999-07-02 2000-06-30 Melagatraani peaaegu kristalne vorm EE200100646A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9902550A SE9902550D0 (sv) 1999-07-02 1999-07-02 New crystalline forms
PCT/SE2000/001398 WO2001002426A1 (en) 1999-07-02 2000-06-30 A substantially crystalline form of melagatran

Publications (1)

Publication Number Publication Date
EE200100646A true EE200100646A (et) 2003-02-17

Family

ID=20416364

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100646A EE200100646A (et) 1999-07-02 2000-06-30 Melagatraani peaaegu kristalne vorm

Country Status (33)

Country Link
US (1) US6479078B1 (is)
EP (1) EP1196431B1 (is)
JP (1) JP2003503508A (is)
KR (1) KR20020020765A (is)
CN (1) CN100537598C (is)
AR (1) AR035553A1 (is)
AT (1) ATE339438T1 (is)
AU (1) AU765614B2 (is)
BR (1) BR0012035A (is)
CA (1) CA2376944A1 (is)
CY (1) CY1107542T1 (is)
CZ (1) CZ20014722A3 (is)
DE (1) DE60030723T2 (is)
DK (1) DK1196431T3 (is)
EE (1) EE200100646A (is)
ES (1) ES2270849T3 (is)
HK (1) HK1045529B (is)
HU (1) HUP0202322A3 (is)
IL (1) IL146972A0 (is)
IS (1) IS6215A (is)
MX (1) MXPA01013441A (is)
MY (1) MY122760A (is)
NO (1) NO20016419L (is)
NZ (1) NZ516187A (is)
PL (1) PL352872A1 (is)
PT (1) PT1196431E (is)
RU (1) RU2243973C2 (is)
SE (1) SE9902550D0 (is)
SK (1) SK18832001A3 (is)
TR (1) TR200103855T2 (is)
TW (1) TWI250991B (is)
WO (1) WO2001002426A1 (is)
ZA (1) ZA200109944B (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6976012B1 (en) 2000-01-24 2005-12-13 Sony Corporation Method and apparatus of using a neural network to train a neural network
US7129233B2 (en) * 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
ES2451140T3 (es) 2003-11-27 2014-03-26 Ajinomoto Co., Inc. Cristal de derivado de fenilalanina y método para su producción
US20050209211A1 (en) * 2004-03-16 2005-09-22 Devalina Law Trihemihydrate, anhydrate and novel hydrate forms of Cefdinir
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MTP1076B (en) * 1990-01-12 1991-09-30 Ciba Geigy Ag Hemihydrate
JPH0687881A (ja) * 1992-09-07 1994-03-29 Asahi Chem Ind Co Ltd ロキタマイシン・一水和物結晶、及びその製造法
JP3077925B2 (ja) * 1992-12-15 2000-08-21 ヤマサ醤油株式会社 ２’−デオキシ−２’−メチリデンシチジン無水物結晶およびその製造法
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
JP3182685B2 (ja) * 1995-09-01 2001-07-03 北陸製薬株式会社 水和物結晶及びその製造方法
JP2914324B2 (ja) * 1995-10-23 1999-06-28 味の素株式会社 ピペリジン誘導体の結晶並びにその製造中間体及び製造方法
TW541316B (en) * 1995-12-21 2003-07-11 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9603724D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
SE9802974D0 (sv) 1998-09-03 1998-09-03 Astra Ab New crystalline forms
FR2793418B1 (fr) 1999-05-11 2001-07-27 Synthelabo Formulations galeniques d'agents antithrombotiques pour administration sous-cutanee

Also Published As

Publication number Publication date
TR200103855T2 (tr) 2002-04-22
DE60030723T2 (de) 2007-11-08
CY1107542T1 (el) 2013-03-13
HK1045529A1 (en) 2002-11-29
WO2001002426A1 (en) 2001-01-11
EP1196431A1 (en) 2002-04-17
IS6215A (is) 2001-12-27
AU765614B2 (en) 2003-09-25
NZ516187A (en) 2004-09-24
AU6040800A (en) 2001-01-22
HUP0202322A2 (en) 2002-10-28
IL146972A0 (en) 2002-08-14
RU2243973C2 (ru) 2005-01-10
PL352872A1 (en) 2003-09-08
US6479078B1 (en) 2002-11-12
HUP0202322A3 (en) 2003-04-28
CN1359389A (zh) 2002-07-17
PT1196431E (pt) 2007-01-31
SK18832001A3 (sk) 2002-10-08
MY122760A (en) 2006-05-31
MXPA01013441A (es) 2002-07-02
BR0012035A (pt) 2002-03-19
EP1196431B1 (en) 2006-09-13
DE60030723D1 (de) 2006-10-26
CA2376944A1 (en) 2001-01-11
ES2270849T3 (es) 2007-04-16
CZ20014722A3 (cs) 2002-05-15
ZA200109944B (en) 2003-03-03
JP2003503508A (ja) 2003-01-28
CN100537598C (zh) 2009-09-09
DK1196431T3 (da) 2006-12-11
KR20020020765A (ko) 2002-03-15
SE9902550D0 (sv) 1999-07-02
TWI250991B (en) 2006-03-11
NO20016419L (no) 2002-03-01
AR035553A1 (es) 2004-06-16
HK1045529B (en) 2007-02-23
ATE339438T1 (de) 2006-10-15
NO20016419D0 (no) 2001-12-28

Similar Documents

Publication Publication Date Title
CY2016002I2 (el) Ν-υποκατεστημενο καρβαμουλοξυαλκυλιο - παραγωγα αζολιου
EE05430B1 (et) Imidasolo-5-l-2-anilino-primidiinid raku proliferatsiooni inhibitsiooni agensitena
EE200100492A (et) Ensüümi IMPDH inhibiitorid
NO20025186L (no) Fremgangsmåte for syntese av en ecteinascidinforbindelse
EP1185528A4 (en) INHIBITORS OF IL-12 PRODUCTION
IS5989A (is) Nýtt kristallað form kalíumsalts (S)-ómeprasóls
NO20022125D0 (no) Pyrrolderivater som inhibitorer for fosfodiesterase VII
NO20020030D0 (no) Krystallinske 1-metylcarbapenemforbindelser
NO20020610L (no) Substituerte 2-dialkylaminoalkylbifenylderivater
EE04234B1 (et) L-fenüülefriinvesinikkloriidi valmistamise meetod
NO20023013L (no) Substituerte 8-arylkinolin-fosfodiesterase-4-inhibitorer
DE60327554D1 (de) Wasserfreies kristallines azidocytosin-hemisulfat-derivat
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
ATE339438T1 (de) Substanziell kristalline form von melagatran
IL150357A0 (en) Substituted piperazine derivatives as mtp inhibitors
NO20022123D0 (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
ATE262517T1 (de) Thiopyranderivate as mmp-inhibitoren
DK1222193T3 (da) Imidazolderivater som phosphodiesterase VII-inhibitorer
EE200200389A (et) Imidasooli uued derivaadid
EE200100537A (et) Maduuraftalasiini derivaatide kasutamine proinflammatoorsete tsütokiinide inhibiitoritena
NO20001985L (no) FremgangsmÕte for forming av strimmelformede folier
PT1175417E (pt) Compostos substituidos de benzolactamas
NO20030416L (no) Krystallinsk terapeutisk forbindelse
ID30381A (id) Penggunaan arilalkanoilpiridazina
HU9904011D0 (en) Novel salts of dipeptid derivatives